CDMO / CMOFounded 2018
AGC Biologics
Bothell, Washington, United States
A biologics-focused CDMO owned by Japan's AGC Inc. (Asahi Glass Company), formed by merging CMC Biologics, Biomeva, and AGC's existing bioscience unit; provides mammalian- and microbial-cell-culture process development and manufacturing of therapeutic proteins, plasmid DNA, mRNA, viral vectors, and engineered cells from sites in the US, Europe, and Japan.
- Segment
- CDMO / CMO
- Headquarters
- Bothell, Washington, United States
- Founded
- 2018
- Website
- www.agcbio.com
Notable facts
- Formed in January 2018 by merging AGC's existing bioscience unit with Biomeva GmbH (Heidelberg) and CMC Biologics, following AGC's 2016 acquisition of CMC Biologics.
- Opened its global headquarters facility in Bothell, Washington in 2018.
- Operates cGMP manufacturing sites in Bothell (Washington), Copenhagen (Denmark), Heidelberg (Germany), Milan (Italy), and Chiba and Yokohama (Japan).
Sourcing guides
Sources. This profile is compiled from public reference data, WebSearch-verified against source 1 · source 2 · source 3. Data as of 2026-07-14. See methodology.
Sourcing a vendor in this segment today? We connect clinical operations, regulatory, and procurement teams with qualified cdmo / cmo vendors.
Request vendors